# EDGAR Filing Document

**Accession Number:** 0001113148
**File Stem:** 0001140361-23-014262
**Filing Date:** 2023-3
**Character Count:** 26514
**Document Hash:** caeeef7267bfeac767365b7370b8921a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-014262.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001140361-23-014262

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 7

**FILED AS OF DATE**: 20230328

**DATE AS OF CHANGE**: 20230328

**EFFECTIVENESS DATE**: 20230328

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INFINITY PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001113148
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 330655706
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270904
- **FILM NUMBER:** 23769939

**BUSINESS ADDRESS:**
- **STREET 1:** 1100 MASSACHUSETTS AVENUE
- **STREET 2:** FLOOR 4
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02138
- **BUSINESS PHONE:** 6174531000

**MAIL ADDRESS:**
- **STREET 1:** 1100 MASSACHUSETTS AVENUE
- **STREET 2:** FLOOR 4
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02138

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INFINITY PHARMACEUTICALS, INC./NEW/
- **DATE OF NAME CHANGE:** 20060913

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DISCOVERY PARTNERS INTERNATIONAL INC
- **DATE OF NAME CHANGE:** 20000428

#### As filed with the Securities and Exchange Commission on March 28, 2023

#### Registration No. 333-

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### <br>

------

### FORM S-8

#### REGISTRATION STATEMENT

#### UNDER

#### THE SECURITIES ACT OF 1933

#### <br>

------

## Infinity Pharmaceuticals, Inc.

#### (Exact Name of Registrant as Specified in Its Charter)

------

---

| | |
|:---|:---|
| **Delaware** | **33-0655706** |
| **(State or Other Jurisdiction of**<br> **Incorporation or Organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **1100 Massachusetts Avenue, Floor 4**<br> **Cambridge, Massachusetts** | **02138** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Inducement Stock Option Award
(Full Title of the Plan)

#### Seth A. Tasker, Esq.

#### Senior Vice President, Chief Business Officer

#### Infinity Pharmaceuticals, Inc.

#### 1100 Massachusetts Avenue, Floor 4

#### Cambridge, Massachusetts 02138
(Name and Address of Agent For Service)

(617) 453-1000

(Telephone Number, Including Area Code, of Agent For Service)

------

#### With copies to:

#### Cynthia T. Mazareas, Esq.

#### Wilmer Cutler Pickering Hale and Dorr LLP

#### 60 State Street

#### Boston, MA 02109

#### Telephone: (617) 526-6000

#### <br>

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

#### PART I

#### INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

**Item 1.** **Plan Information.**<br>

The information required by Item 1 is included in documents sent or given to the participant in the Inducement Award covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act").

**Item 2.** **Registrant Information and Employee Plan Annual Information.**<br>

The written statement required by Item 2 is included in documents sent or given to the participant in the Inducement Award covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.

#### PART II

#### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

**Item 3.** **Incorporation of Documents by Reference.**<br>

The registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the "Commission"). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:

(a) The Registrant's annual Report on [Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001113148/000111314823000003/infi-20221231.htm) for the year ended December 31, 2022, filed with the Commission on March 28, 2023;

(b) All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the document referred to in (a) above.

(c) The description of the securities contained in the Registrant's registration statements on Form 8-A filed under the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

**Item 4.** **Description of Securities.**<br>

Not applicable.

**Item 5.** **Interests of Named Experts and Counsel.**<br>

Wilmer Cutler Pickering Hale & Dorr LLP has opined as to the legality of the securities being offered by this Registration Statement.

------

**Item 6.** **Indemnification of Directors and Officers.**<br>

Section 145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, *provided* that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, *provided* that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

Section 102(b)(7) of the DGCL provides, generally, that our certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, *provided* that such provision may not eliminate or limit the liability of a director (i) for any breach of the director's duty of loyalty to the corporation or its shareholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit. No such provision may eliminate or limit the liability of a director for any act or omission occurring prior to the date when such provision became effective.

The Registrant's certificate of incorporation provides that a member of its board of directors will not be personally liable to the Registrant or its stockholders for monetary damages for breaches of their fiduciary duties to the Registrant or its stockholders as a director, except for liability:

<br> • for any breach of the director's duty of loyalty to the Registrant or its stockholders;

<br> • for acts or omissions by the director not in good faith or which involve intentional misconduct or a knowing violation of law;

<br> • for declaring dividends or authorizing the purchase or redemption of shares in violation of Delaware law; or

<br> • for transactions where the director derived any improper personal benefit.

The Registrant's certificate of incorporation also allows it to indemnify directors and officers to the fullest extent authorized by Delaware law.

The Registrant's bylaws provide that it shall, to the fullest extent authorized by the DGCL, indemnify its directors and executive officers; provided, however, that it may limit the extent of such indemnification by individual contracts with its directors and executive officers; and, provided, further, that the Registrant shall not be required to indemnify any director or executive officer in connection with any proceeding (or part thereof) initiated by such person or any proceeding by such person against the Registrant or its directors, officers, employees or other agents unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by the Registrant's board of directors, or (iii) such indemnification is provided by the Registrant, in its board's sole discretion, pursuant to its powers under the DGCL.

The Registrant's bylaws also permit it to maintain insurance to protect it and any director, officer, employee or agent against any liability with respect to which the Registrant would have the power to indemnify such persons under the DGCL. The Registrant maintains an insurance policy insuring its directors and officers against certain liabilities.

**Item 7.** **Exemption from Registration Claimed.**<br>

Not applicable.

------

**Item 8.** **Exhibits.**<br>

---

| | |
|:---|:---|
| Number | Description |
| [4.1](https://www.sec.gov/Archives/edgar/data/1113148/000111314820000028/restatedcertificateofi.htm) | Restated Certificate of Incorporation of the Registrant, as amended (previously filed as Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended July 30, 2020 (File No. 000-31141) and incorporated herein by reference). |
| [4.2](https://www.sec.gov/Archives/edgar/data/1113148/000111314823000003/exhibit32amendedbylaws.htm) | Amended and Restated Bylaws of the Registrant (previously filed as Exhibit 3.2 to the Registrant's Annual Report on Form 10-K filed on March 28, 2023 (File No. 000-31141) and incorporated herein by reference). |
| [5.1](brhc10050177_ex5-1.htm) | Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant. Filed Herewith. |
| [23.1](brhc10050177_ex5-1.htm) | Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1). Filed Herewith. |
| [23.2](brhc10050177_ex23-2.htm) | Consent of Ernst & Young LLP, independent registered public accounting firm to the Registrant. Filed Herewith. |
| [24.1](#POWEROFATTORNEYANDSIGNATU) | Power of attorney (included on the signature pages of this Registration Statement). |
| [99.1](https://www.sec.gov/Archives/edgar/data/1113148/000114036121026429/nt10024341x4_ex99-1.htm) | Form of Nonstatutory Stock Option Award Agreement for Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635 (c)(4) (previously filed as Exhibit 99.1 to the Registrant's Form S-8 Registration Statement filed on August 2, 2021 (File No. 333-258360) and incorporated herein by reference). |
| [107.1](brhc10050177_ex107.htm) | Filing Fee Table |

---

**Item 9.** **Undertakings.**<br>

1. *<u>Item 512(a) of Regulation S-K</u>*. The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

*provided, however,* that paragraphs (1)(i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

2. *<u>Item 512(b) of Regulation S-K</u>*. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

------

3. *<u>Item 512(h) of Regulation S-K</u>*. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

#### SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts, on this 28th day of March, 2023.

---

| | |
|:---|:---|
| **INFINITY PHARMACEUTICALS, INC.** | **INFINITY PHARMACEUTICALS, INC.** |
| By: | /s/ Lawrence E. Bloch |
|  | Lawrence E. Bloch, M.D., J.D. |
|  | President |

---

#### POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Infinity Pharmaceuticals, Inc., hereby severally constitute and appoint Adelene Q. Perkins, Lawrence E. Bloch, M.D., J.D., and Seth A. Tasker, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the Registration Statement on Form S-8 filed herewith and any and all subsequent amendments to said Registration Statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Infinity Pharmaceuticals, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said Registration Statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933 Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| Signature | Title | Date |
| /s/ Adelene Q. Perkins | Chief Executive Officer and Chair of the Board of Directors (Principal Executive Officer) | March 28, 2023 |
| Adelene Q. Perkins | Chief Executive Officer and Chair of the Board of Directors (Principal Executive Officer) | March 28, 2023 |
| /s/ Lawrence E. Bloch | President (Principal Financial Officer and Principal Accounting Officer) | March 28, 2023 |
| Lawrence E. Bloch, M.D., J.D. | President (Principal Financial Officer and Principal Accounting Officer) | March 28, 2023 |
| /s/ Samuel Agresta | Director | March 28, 2023 |
| Samuel Agresta, M.D., M.P.H. | Director | March 28, 2023 |
| /s/ David Beier | Director | March 28, 2023 |
| David Beier, J.D. | Director | March 28, 2023 |
| /s/ Anthony B. Evnin | Director | March 28, 2023 |
| Anthony B. Evnin, Ph.D. | Director | March 28, 2023 |
| /s/ Richard Gaynor | Director | March 28, 2023 |
| Richard Gaynor, M.D. | Director | March 28, 2023 |
| /s/ Sujay R. Kango | Director | March 28, 2023 |
| Sujay R. Kango | Director |  |
| /s/ Brian Schwartz | Director | March 28, 2023 |
| Brian Schwartz, M.D. | Director |  |
| /s/ Norman C. Selby | Director | March 28, 2023 |
| Norman C. Selby | Director | March 28, 2023 |

---

------

## Exhibit 5.1

------

![](image00002.jpg)

---

| | |
|:---|:---|
| March 28, 2023 | **Exhibit 5.1** |
|  | + 1 617 526 6000 (t) |
| Infinity Pharmaceuticals, Inc.<br> 1100 Massachusetts Avenue, Floor 4<br> Cambridge, Massachusetts 02138 | + 1 617 526 5000 (f)<br>|

---

Re: <u>Registration Statement on Form S-8; Inducement Option Agreement (as defined below)</u>

Ladies and Gentlemen:

We have assisted in the preparation of a Registration Statement on Form S-8 (the "Registration Statement") to be filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), relating to an aggregate of 30,000 shares of common stock, $0.001 par value per share (the Common Stock"), of Infinity Pharmaceuticals, Inc., a Delaware corporation (the "Company"), consisting of 30,000 shares of Common Stock issuable pursuant to an inducement stock option agreement between the Company and Kenneth Duong entered into on April 6, 2022 (the "Inducement Option Agreement").

We have examined the Certificate of Incorporation and By-Laws of the Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the board of directors and stockholders of the Company, the Registration Statement and such other documents relating to the Company as we have deemed material for the purposes of this opinion.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.

We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Inducement Option Agreement, to register and qualify the Shares for sale under all applicable state securities or "blue sky" laws.

We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.

![](image00003.jpg)

------

---

| | |
|:---|:---|
| Infinity Pharmaceuticals, Inc.<br> March 28, 2023<br> Page 2<br>|  |
|  | ![](image00001.jpg) |

---

It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Inducement Option Agreement, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,

---

| | |
|:---|:---|
| By: | <u>/s/ Wilmer Cutler Pickering Hale and Dorr LLP</u> |
|  | WILMER CUTLER PICKERING |
|  | HALE AND DORR LLP |

---

------

## Exhibit 23.2

------

**Exhibit 23.2**<br>

**** 

<br> #### Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Inducement Stock Option Award of Infinity Pharmaceuticals, Inc. of our report dated March 28, 2023, with respect to the consolidated financial statements of Infinity Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 28, 2023

------

## Ex-Filing

------

#### Exhibit 107

#### Calculation of Filing Fee Tables

#### Form S-8
(Form Type)

#### Infinity Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)

#### Table 1—Newly Registered Securities

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security**<br> **Type** | **Security Class**<br> **Title** | **Fee**<br> **Calculation**<br> **Rule** | **Amount**<br> **Registered**<br> (1) | **Proposed**<br> **Maximum**<br> **Offering**<br> **Price Per**<br> **Unit** | **Maximum**<br> **Aggregate**<br> **Offering Price** | **Fee Rate** | **Amount of**<br> **Registration**<br> **Fee** |
| Equity | Common Stock, $0.001 par value per share | Other | 30,000 shares (2) | $0.1921 (3) | $5763.00 (3) | $110.20<br> per $1,000,000 | $0.64 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $5763.00 |  | $0.64 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $0.64 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any additional securities that may from time to time be
 offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Consists of 30,000 shares issuable under a nonstatutory stock option award pursuant to a nonstatutory stock option agreement entered into by the Registrant with Kenneth Duong, the Registrant's Associate
 Director, Supply Operations, which was granted on April 6, 2022 in accordance with Nasdaq Listing Rule 5635(c)(4).

&nbsp;&nbsp;&nbsp;&nbsp;(3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The price per share and aggregate offering price are calculated on the basis of
 the average of the high and low sale prices of the registrant's common stock on the Nasdaq Global Market on March 24, 2023, in accordance with Rule 457(c) under the Securities Act.

------